Myriad Genetics Stock
Myriad Genetics Stock
A loss of -1.090% shows a downward development for Myriad Genetics.
Our community is currently high on Myriad Genetics with 5 Buy predictions and 2 Sell predictions.
With a target price of 23 € there is a positive potential of 27.07% for Myriad Genetics compared to the current price of 18.1 €.
Pros and Cons of Myriad Genetics in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Myriad Genetics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Myriad Genetics | -1.090% | 9.581% | -7.107% | -4.688% | 3.390% | -26.683% | -37.734% |
| Integer Hldg | -2.880% | -11.111% | -0.952% | 42.466% | 16.854% | 35.948% | 61.994% |
| Healthequity Inc. | - | 0.000% | -3.289% | 58.405% | 23.529% | 17.262% | - |
| Omnicell Inc. | - | 0.800% | -0.787% | -52.897% | -28.000% | -78.824% | -64.497% |
Comments
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $28.00 to $31.00. They now have a "buy" rating on the stock.
Show more
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) is now covered by analysts at Guggenheim. They set a "buy" rating and a $23.00 price target on the stock.
Show more
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $28.00 price target on the stock.
Show more
Ratings data for MYGN provided by MarketBeat